Koo J Y
Department of Dermatology, University of California, San Francisco Medical Center, USA.
Cutis. 1998 Feb;61(2 Suppl):36-7.
When a new class of topical medication becomes available to treat psoriasis, its optimal usage may not be fully defined for years. This is because even the "experts" who tested the medication in clinical research and reviewed the scientific literature may have limited experience with its use in actual clinical practice. Eventually, the optimal usage will probably be defined by the sum total of the practitioner's experience with it, rather than by the researchers who investigated the agent initially. However, with that limitation in mind, and based on available information, one can start to define where this agent is likely to show its greatest advantage. Three areas of possible strength, and one situation where tazarotene might not show its best advantage, will be discussed in detail.
当一种新型局部用药可用于治疗银屑病时，其最佳用法可能多年都无法完全明确。这是因为即使是在临床研究中测试该药物并查阅科学文献的“专家”，在实际临床实践中使用它的经验也可能有限。最终，最佳用法可能由从业者使用该药物的全部经验来确定，而不是由最初研究该药物的研究人员来确定。然而，考虑到这一局限性，并基于现有信息，人们可以开始确定这种药物可能显示出最大优势的领域。将详细讨论三个可能具有优势的领域，以及一种他扎罗汀可能无法展现其最佳优势的情况。
